CDI Laboratories, Inc.
Guanajibo Research and Innovation Park
4005 Street B, Road 114 Km 1.3
Mayaguez
Puerto Rico
00682
United States
Tel: 787-806-4006 and 844-539-6296
Website: http://www.cdi-lab.com/
Email: sales@cdi-lab.com
About CDI Laboratories, Inc.
CDI delivers products and services based on its ultra-high content human proteome microarray technology (HuProt) as well as monoclonal antibody production. CDI antibodies are screened for off-target cross-reactivity using HuProt, resulting in unsurpassed specificity and reliability. The Company's products and services help to overcome technical challenges that hinder advancements in research proteomics and in the development of protein-based therapeutics and diagnostics.YEAR FOUNDED:
2002
LEADERSHIP:
Founders: Ignacio Pino, Daniel Eichinger, Jef Boeke, and Joe Bonaventura
Founder and CEO: Ignacio Pino
JOBS:
Please click here for CDI Labs job opprotunities.
CLINICAL TRIAL:
Please click here for clinical trial information.
PRODUCTS:
All Products
FOLLOW CDI LABORATORIES:
Tweets by CDI Laboratories
11 articles about CDI Laboratories, Inc.
-
Barney E. Saunders Ph.D. has been appointed Chief Executive Officer of CDI Laboratories
8/2/2023
CDI Laboratories Inc., the Seromics™ company, announced that Barney E. Saunders Ph.D. has been appointed Chief Executive Officer.
-
BroadOak Capital Partners Invests in CDI Laboratories to Expand and Scale Antibody Biomarker Discovery Platforms
1/9/2023
CDI Laboratories, Inc announced that it has received a significant investment from BroadOak Capital Partners that will enable CDI Labs to meet increased demand for its HuProtTM proteome microarray autoantibody biomarker discovery product line and launch new phage display immunoprecipitation sequencing services.
-
CDI Labs HuProt™ Protein arrays instrumental in recent study of Multisystem Inflammatory Syndrome in Children (MIS-C)
9/23/2020
CDI Laboratories, Inc. HuProt™ protein microarray provided important data on a recent high impact paper comparing the immune profiles of MIS-C, healthy children and individuals with COVID-19.
-
CDI Labs Launches its SARS-CoV-2 (COVID19) service platform
8/20/2020
CDI Laboratories, Inc. announced the addition of its SARS-CoV-2 (COVID19) assay platform. The assays use CDI's VirScan service which can detect antibodies to 1345 individ
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 5, 2020.
-
CDI Labs Launches Two New Powerful Assays to its Biomarker Discovery Platform
2/4/2020
Proteomics company CDI adds HuScan™ (PhIP-Seq patient biomarker discovery platform) and VirScan™ (PhIP-Seq antibody detection assays that includes every known human and viral protein).
-
CDI Labs Releases HuProt™ v4.0 - Adding additional content to Largest Content Human Proteome Microarray in the World
3/5/2019
Proteomics company now producing glass slides printed with recombinant human proteins containing over 21,000 human proteins and protein isoforms, including >81% of canonically expressed proteins as defined by the Human Protein Atlas for high throughput analytics, contract research and hybridoma development services.
-
CDI Labs Collaborates on Discovery of New Biomarkers for Zika Infection
3/8/2018
Proteomics company leverages microarray capability to develop a high-throughput test that detects and discriminates between Zika and Dengue viruses
-
CDI Labs Cites New Research Identifying Early Lung Cancer Autoantibody Biomarkers using HuProt
11/28/2017
Newly published research in the Journal of Molecular and Cellular Proteomics describes a collection of autoantibody biomarkers for early detection of lung cancer.
-
CDI Laboratories Expands HuProt - The Highest Content Human Proteome Microarray In The World
5/26/2017
-
CDI Laboratories And NeoBiotechnologies Form Alliance To Distribute CDI's 2500 Monospecific Transcription Factor Antibodies
4/21/2017